CRP and gastric cancer: As Figure 3C and Figure S5B show, a significant improved prognosis from ACT was observed when compared with surgery only in the high‐post‐CRPmax subgroup of high‐pre‐CRP GC (3‐year RFS: 50.1% vs 30.8% in chemotherapy and surgery only groups, respectively; p = 0.014; 3‐year OS: 47.0% vs 23.1% in chemotherapy and surgery only groups, respectively; p = 0.003).